Introduction
Testicular germ cell tumors (TGCTs) retain pluripotent potential and are thought to arise from transformation of primordial germ cells (Andrews, 1998; Chaganti and Houldsworth, 2000) . Embryonal carcinoma (EC) represents the stem cell component of TGCTs and certain human EC lines such as the NT2/D1 line, retain pluripotency and share striking similarities with human embryonic stem cells including highly similar patterns of gene expression (Sperger et al., 2003) . NT2/D1 cells were derived from a metastasis of a TGCT patient and retain the major cytogenetic and cellular features of these tumors (Sperger et al., 2003) . NT2/D1 cells are highly malignant but can be induced to differentiate and lose tumorigenicity with all-trans retinoic acid (Andrews, 1998; Spinella et al., 2003) . Thus, they are an excellent model of differentiation of tumor cells and pluripotent stem cells.
TGCTs are cured at a rate of greater than 80% with conventional cisplatin-based chemotherapy even when highly advanced (Einhorn, 2002) . These responses have been linked to rapid and extensive apoptosis in vitro and in vivo (Spierings et al., 2003a) . However, the remaining 10-20% of patients are refractory to treatment and most eventually die from progressive disease (Einhorn, 2002) . Various attempts have been made to understand the unique sensitivity of these tumors to therapy as well as the reasons for resistance; however to date, no explanation has been generally accepted. Suggested mechanisms that may play a role in cisplatin sensitivity of TGCTs include diminished drug exporters and detoxifiers, low levels of DNA repair proteins, and a high Bax/Bcl-2 ratio (reviewed in Masters and Koberle, 2003; Spierings et al., 2003a) .
One relatively unique feature of TGCTs is the expression of higher than normal levels of wild-type p53 that is otherwise commonly mutated in over 50% of solid human tumors and in almost all tumor types (Peng et al., 1993) . We and others have shown that p53 is latent in EC but can be activated by DNA damage or differentiation agents (Lutzker and Levine, 1996; Curtin et al., 2001) . Thus, the lack of p53 mutations in TGCTs may be due to a lack of selective pressure during TGCT progression. However, the evidence is conflicting as to the importance of p53 in cisplatin hypersensitivity of TGCTs. Several in vivo and in vitro studies suggest an important role for p53 in TGCT cisplatin responses (Zamble et al., 1998; Curtin et al., 2001; Lutzker et al., 2001) . In contrast, other studies have failed to support a role for p53 (Burger et al., 1999; Kersemaekers et al., 2002) . These conflicts may be due to inherent differences in murine versus human models of TGCTs, and to differences in the dosages and assays used to assess relative cisplatin sensitivities. The specificity of target gene activation by p53 is modulated by coactivators whose activity and expression may result in cell contextdependent responses to p53 activation (Fei et al., 2002) . Since it has been convincingly shown that in certain tumor contexts p53 protects cells from cisplatin toxicity due to induction of G1 arrest (Bunz et al., 1999) , the role of p53 in TGCT response remains controversial, and important pathways downstream of p53 remain poorly understood.
In the current study, we used expression array profiling to assess, for the first time, the global transcriptional response of TGCTs to cisplatin treatment. This response appears specific to TGCTs and is dominated by the transcription factor p53, which we have validated as an important target of cisplatinmediated gene expression and cytotoxicity in TGCTs.
Results

Microarray analysis uncovers prominent p53 target gene induction following cisplatin treatment
We previously demonstrated that NT2/D1 cells are sensitive to cisplatin-mediated apoptosis (Curtin et al., 2001) . To better study early events following cisplatin treatment, preliminary experiments were conducted employing a brief treatment protocol with recovery to assess the cellular response to a 'fixed' level of DNA damage. Adherent cells treated for 6 h with a 0.5 mM dose of cisplatin had not yet undergone apoptosis as measured by sub-G1 content (Figure 1a ). Modest apoptosis was seen in floating cells (data not shown). Both adherent and floating cells underwent apoptosis at 48 h or with a higher concentration of cisplatin ( Figure 1a ). Survival assays of cells treated with the indicated doses of cisplatin for 6 h shows an approximate 60% decrease in cell viability with a 0.5 mM cisplatin dose (Figure 1b ). Thus, 6 h of 0.5 mM cisplatin treatment and 24-h recovery was chosen for subsequent expression profile analysis on adherent cell populations.
Treated microarray hybridizations were performed in duplicate on separate days. Cisplatin-treated cells were compared with control untreated NT2/D1 cells. Data were analysed using Gene Traffic Software (Iobion). Criteria for gene selection was a fold-change of greater than or equal to 2.0 in one of the two hybridizations and a fold-change of greater than or equal to 1.5 in the remaining hybridization compared to control. This was chosen because the second experiment had generally modest fold-changes even though the top 50 genes were highly similar in both experiments. In total, 51 genes met these criteria with 46 genes induced and only five repressed with cisplatin treatment. The identity and associated function of each gene is provided in Table 1 . Notably, 25 of the 46 induced genes have previously been identified as p53 target genes (Kannan et al., 2001; Sax and El-Deiry, 2003; Kho et al., 2004) (bold in  Table 1 ), including nine of the top 10 genes ranked according to fold-change. The exception is the hypothetical protein FLJ11259, which is a potential novel p53 target.
Cisplatin treatment engaged the apoptotic machinery at multiple levels. Highly represented were genes involved in the extrinsic death receptor pathway of apoptosis including FAS, TRAILR3, PHLDA3, LRDD, and IER3 (Thorburn, 2004) . Another set of genes identified as induced by cisplatin treatment of NT2/D1 cells are involved in the regulation of reactive oxygen species (ROS), including SESN1, FDXR, PLK3, and DDIT4 (Martindale and Holbrook, 2002) . BTG2, DDB2, p21, GDF15, WIG1, GADD45, and TRIM22 are involved in the response to DNA damage and many of the genes are involved in cell cycle arrest, negative regulation of cell proliferation, or apoptosis (Debatin, 2004) . Interestingly, three serine/threonine kinases thought to be involved in apoptosis were induced, the Fold-change is given for two independent microarray hybridization experiments. Bold-faced genes are previously known to be targets of p53.
(1) Indicates prior direct experimental evidence for a p53 target gene. (2) Indicates evidence for p53 target gene based on previous p53-specific microarray (Kannan et al., 2001; Sax and El-Diery, 2003; Kho et al., 2004) . (NA) Indicates the information concerning a p53 target is not available. *Indicates a gene confirmed in this study by Northern or RT-PCR analysis to be induced by cisplatin and sensitive to p53 siRNA polo-like kinases, PLK2 and PLK3, and STK17A (Debatin, 2004) . Other notable drug targets are the orphan G protein-coupled receptor GPR95 and the 2C phosphatase, PPMID. Many genes involved in phospholipid signaling and metabolism were induced, including DGKA, ANXA4, PDE4A, ISYNA1, PROCR, and INPP5D (Wright and McMaster, 2002) . Interestingly, and in contrast to our previous array studies with retinoic acid in the same cells (Freemantle et al., 2002) , few transcription factors were regulated by cisplatin, exceptions are MYC and HESX1. According to unbiased Gene Ontology analysis, the predominating pathways regulated by cisplatin in NT2/D1 cells were those involved in the response to stress and DNA damage, along with genes involved in cell death, apoptosis, and negative regulation of the cell cycle.
Select cisplatin responsive genes are dependent on p53
Expression profiling suggested an important role for p53 in the response of NT2/D1 cells to cisplatin. We employed RNAi technology to directly investigate p53-dependence of cisplatin target genes. Two independent siRNA sequences were designed. Both p53 siRNAs, but not a control siRNA, greatly diminished p53 mRNA ( Figure 2a ) as well as basal and cisplatin-induced p53 protein expression (Figure 2a ). The cisplatin-induced expression of the p53 target gene p21 was also greatly reduced in p53 siRNA cells. Further, p53 siRNA but not control siRNA greatly diminished p53 transactivational activity as measured by an MDM2-based reporter assay to a level comparable to a previously characterized DN-p53 construct ( Figure 2b ) (Curtin et al., 2001) . Thus, the p53 siRNA employed was able to potently and specifically inhibit known p53 responses in NT2/D1 cells. Additionally, cisplatin-induced expression of p21 could be rescued in p53 siRNA cells with expression of an siRNA-resistant form of wild-type p53 (data not shown). The effect of p53 knockdown on cisplatin target genes was then investigated. Cisplatin induction of all genes tested (18 of 18) was confirmed through Northern or RT-PCR analysis (Figure 2c and data not shown). These genes are highlighted by an asterisk in Table 1 . Surprisingly, cisplatin induction of all 18 genes was at least partially dependent on p53. As depicted in Figure 2c , p53 siRNA but not control siRNA diminished cisplatin-mediated expression of genes known to be targets of p53 as well as other genes investigated from the array analysis. In general, there was good correlation between toxic doses of cisplatin able to activate caspase 3 and induction of the array genes (Figure 3a) . The genes were also induced by etoposide, another chemotherapeutic drug for which TGCTs are hypersensitive, but not with toxic, caspase 3-activating, doses of anisomycin, a drug that does not activate p53 under the conditions employed (Figure 3a) . Thus, the expression of these genes are not specific to cisplatin per se but are likely induced as a general response to genotoxic stress in which TGCTs are known to be hypersensitive. As a control, the trans isomer of cisplatin at doses as high as 10 mM did not induce p53 or the investigated genes from the microarray (Figure 3b ). This is an important control since transplatin and cisplatin have very similar chemistry and can form adducts with DNA and proteins, yet they have different clinical effects (Jakupec et al, 2003) . Transplatin is ineffective in the clinic and the result that transplatin does not induce p53 or the cisplatin target genes suggest that the genes in Table 1 are induced in relation to cisplatin-mediated cellular toxicity and not to a nonspecific effect of platinated compounds.
FDXR and FAS are induced at the protein level with cisplatin treatment in a manner that is partially p53 dependent (Figure 4a ). These genes are also induced in the presence of the caspase 3 inhibitor (Z-Vad-FMK) at concentrations that inhibit poly(ADP-ribose) polymerase (PARP) cleavage (Figure 4b ). This result demonstrates that induction of the cisplatin target genes are not due to the secondary effects downstream of apoptosis.
Global cisplatin response is dependent on p53
In order to survey the global effects of p53 knockdown on cisplatin-mediated changes in gene expression in NT2/D1 cells, microarray experiments were repeated in p53 siRNA cells. Figure 5a depicts the expression profile of untreated NT2/D1 cells compared with that of untreated p53 siRNA cells. A small set of genes changed basally with p53 knockdown, but were not classic p53 targets. There was also no overlap between these genes and the cisplatin-regulated genes in Table 1 (represented in the scatter plot in Figure 5b ). This is consistent with our findings and those of others that p53 is basally latent in EC and TGCTs (Lutzker and Levine, 1996; Curtin et al., 2001) . Reassuringly, the gene repressed to the greatest extent basally with p53 knockdown was p53, which was represented by two probe sets in the scatter plot in Figure 5a (repressed 4.31-and 4.11-fold). This confirmed specific and potent targeting of p53 with siRNA. The next highest changed gene was regulator of G-protein signaling 5; RGPS5 (induced 3.82-fold). Only 12 additional genes changed twofold or greater, the majority induced, and include lipase A (LIPA), stearoylCoA desaturase (SCD), DEAD-box protein 3, Y-linked (DDX3Y), and myosin light polypeptide 9 (MYL9). This may be due to relief of basal repression by p53 or nonspecific effects of the siRNA or transfection procedure.
Interestingly, direct comparison of wild-type and p53 siRNA cells indicated dramatic repression of cisplatin regulation in p53 siRNA cells (compare Figure 5b with Figure 5c ). In fact, only two genes were changed 1.8-fold or higher with cisplatin treatment of p53 siRNA cells. These were DEAH box polypeptide 9 (DHX9) and coatomer protein complex subunit a (COPA). Five of the top six cisplatin-induced genes in wild-type NT2/D1 cells were GDF15 (8.93), p21 (3.83), FLJ11259 (3.72), BTG2 (3.53), and FAS (3.32), (Table 1) . These same genes in p53 siRNA cells had fold-inductions between 1.3-and 1.5-fold. A total of 11 genes from Table 1 were induced in p53 siRNA cells but to a lesser extent Table 1 . Cells were treated as in Figure 2a and RT-PCR analysis was performed for the indicated genes. Fold-induction compared to untreated wild-type cells as determined by densitometry is indicated below each band. In indicated samples (ÀRT), reverse transcriptase was omitted to control for genomic contamination. Representative of two independent experiments. (*) Indicates genes known from prior studies to be p53 targets (1.4-1.7-fold) compared to wild-type cells. They are DDB2, SESN1, RPS27L, TRIM22, ANXA1, BTG2, FDXR, GADD45A, STK17A, ANXA4 and C12orf4. Similar results were obtained for a second independent siRNA for p53 (data not shown). These results support direct examination of the genes in Figure 2c , and suggests that p53 participates in a majority of cisplatin transcriptional effects in human embryonal carcinoma cells, thereby linking p53 and specific p53 targets with cisplatin hypersensitivity of TGCTs. (Scb) or p53 siRNA cells were untreated or treated with 10 mM cisplatin or 10 mg/ml anisomycin and analysed for loss of mitochondrial membrane potential using DiOC 6 staining and FACS analysis as described in Material and methods. Percentages indicate number of cells with membrane potential loss. Cisplatin treatment was for 6 h followed by 24 h incubation in drug-free media. Anisomycin treatment was for 4 h. Adherent and floating cells were assessed in all cases brief high-dose treatment employed, was more effective in p53 siRNA cells compared to controls (Figure 6b) . Together, these data support a functional role for p53 in sensitizing human embryonal carcinoma cells to cisplatin cytotoxicity.
Discussion
TGCTs are a model of solid tumor curability. Most investigated mechanisms of TGCT sensitivity have been based on profiling various candidate proteins including p53 and other proteins of the apoptotic and DNA repair machinery, prospectively in clinical samples. For example, it has been reported that no correlation exists between the levels of p53 or its targets and clinical outcome in TGCTs (Kersemaekers et al., 2002) . However, key downstream targets mediating the unique therapeutic response of TGCTs may be anticipated to be acutely and transiently altered during therapy. Using a widely characterized in vitro model of TGCTs we have surveyed, for the first time, the global transcriptional response of TGCTs to a chemotherapeutic regimen. The majority of the genes induced in response to cisplatin are generally known to be involved in apoptotic and antitumor responses, suggesting that the cellular context of TGCTs may be inherently sensitive or 'primed' to respond to DNA-damaging agents. This may reflect their germ cell origins since male germ cells undergo a high degree of spontaneous apoptosis, which is suggested to be a safeguard for deleterious mutations in the germ line (Schrader et al., 2001) .
Previously, p53 has been implicated in the curability of TGCTs. However, the results to date have been contradictory (Zamble et al., 1998; Burger et al., 1999; Lutzker et al., 2001; Kersemaekers et al., 2002) . Our results suggest that p53 is directly involved in cisplatin hypersensitivity of TGCTs. Microarray analysis following acute cisplatin treatment uncovered a high percentage of previously identified p53 transcriptional targets (Kannan et al., 2001; Sax and El-Deiry, 2003; Kho et al., 2004) . Silencing of p53 in TGCTs protected the cells from cisplatin-mediated toxicity and diminished global cisplatin-induced gene expression. This may represent a unique signature in the context of EC, since published genome-wide p53 target gene analysis has shown celltype-specific responses to p53 activation (Kannan et al., 2001; Fei et al., 2002; Sax and El-Deiry, 2003; Kho et al., 2004) . Furthermore, other tumor types typically appear to have large p53-independent contributions to cisplatin and other DNA-damaging agents (Bunz et al., 1999; Niedner et al., 2001) . It is tempting to speculate that the pluripotent character of TGCTs provides greater genome-wide accessibility to transcriptional regulation in response to p53 compared with other solid tumors, and that this may be related to the sensitivity of TGCT to cisplatin and other DNA-damaging agents (Andrews, 1998; Chaganti and Houldsworth, 2000) . Although p53 siRNA conferred modest (B3-fold) decreased sensitivity to cisplatin, this corresponds with several previous studies showing that TGCT lines have a 2-4-fold greater cisplatin sensitivity compared to various other cancer types, which has been suggested to account for the difference between cure and failure in the clinical setting of large tumor burden (reviewed in Masters and Koberle, 2003) . It is important to note that the genes uncovered here may be generally involved in the hypersensitivity of TGCTs in response to DNA damage. In fact several of the genes analysed were also induced by etoposide (Figure 3 ). Whether any of the genes are uniquely regulated by cisplatin will be addressed in future studies.
Predominating pathways shown here to be activated by cisplatin include those involved in response to DNA damage and events leading to cell death (Martindale and Holbrook, 2002; Wright and McMaster, 2002; Debatin, 2004; Thorburn, 2004) . Multiple components of the apoptotic machinery were engaged. It is of interest that the extrinsic, death receptors pathway of apoptosis appeared to be widely targeted (Thorburn, 2004) (Table 1 ). This included the death receptor gene FAS, the FAS adaptor LRDD, and a gene implicated in positive FAS regulation, PHLDA3. This suggests that transcriptional upregulation of death receptor pathway genes may contribute to, or amplify, cisplatin-mediated apoptosis in TGCTs. However, two other genes TRAILR3 and IER3, thought to inhibit TNF and FAS death receptor signaling, respectively, were also induced, suggesting complex regulation of the pathway (Thorburn, 2004) . The Fas/FasL system has been previously shown to be active in TGCTs (Spierings et al., 2003b) .
Another apoptotic signaling pathway represented by several genes on the array was ROS generation (Martindale and Holbrook, 2002) (Table 1) . ROS generation is yet to be widely studied in the context of TGCTs. A key p53 target of the mitochondrial pathway, Bax did not make the cutoff used here (Sax and El-Deiry, 2003) . Further, our study does not address several transcription-independent mechanisms of p53-mediated apoptosis including the recent demonstration of a direct p53-Bax interaction (Chipuk et al., 2004) . Importantly, but beyond the scope of the current study, it is of interest to establish the extent to which induced transcript levels correlate with protein expression. It will be of importance to dissect the relative role of each apoptotic pathway in the cisplatin response of TGCTs as well as the significance of the individual genes of each pathway highlighted here. Further characterization of new p53 targets will increase our understanding of carcinogenesis and therapy.
In summary, we propose that hyperactivation of p53 may provide a small but sufficient increased susceptibility of TGCTs to chemotherapy not shared by the majority of solid tumors. The genes identified here including those implicated to be novel p53-responsive may provide new opportunities for therapeutic intervention in TGCT and other less curable cancers. Further studies will be required to uncover the biologic and therapeutic impact of these genes in TGCTs.
Materials and methods
Cell culture and drug treatments
NT2/D1 is a clonal line derived from a xenograph of Tera-2 cells (Andrews, 1998) . NT2/D1 cells were cultured in DMEM media (Gibco) with 10% FBS supplemented with glutamine and antibiotics. Cisplatin (Bristol Laboratories), etoposide (Sigma), transplatin (Sigma), and anisomycin (Sigma) treatments were performed in the same media at the concentrations and time points indicated. The caspase-3 inhibitor Z-VAD-FMK (Calbiochem) was used at a concentration of 50 mM. For microarray analysis, log-phase cells were treated with 0.5 mM cisplatin for 6 h, then washed and placed in fresh drug-free media for 24 h prior to harvesting adherent cells. An identical protocol of 6 h cisplatin treatment, 24 recovery, and adherent cell harvest was performed for mRNA and protein expression analysis. For cell survival assays, cells were seeded at 5 Â 10 4 cells per well of a six-well dish and allowed to grow for 4-5 days after 6 h of cisplatin treatment. Cells were stained with Trypan blue and counted by hemocytometer. For cell cycle analysis, adherent or adherent plus floating cells were fixed in 70% ethanol and stained for 16 h with propidium iodide prior to analysis on a BD bioscience FACScan flow cytometer. Mitochondrial membrane potential was assessed using 3,3-dihexyloxacarbocyanine (DiOC 6 ) (Molecular Probes) using a previously described method (Zamzami et al., 1995) . After drug treatment, adherent and floating cells (2 Â 10 5 ) were incubated with 40 nM DiOC 5 in PBS for 15 min at room temperature and assayed by FACS analysis. Cell Quest software was used to calculate the percentage of cells exhibiting decreased DiOC 6 fluorescence (membrane potential loss) relative to viable untreated control cells. Anisomycin (Sigma) was used at a concentration of 10 mg/ml.
Transient transfection reporter assays
The reporter MDM2-Luc has been previously described (Curtin et al., 2001) . In all, 1.75 Â 10 5 cells per well of a sixwell plate were transfected with 2.5 mg DNA including 0.5 mg of reporter plasmid and 0.1 mg pRL-TK plasmid (renilla luciferase) using Polyfect (Qiagen) according to the manufacturer's directions. RNAi experiments were performed as previously described using 1.5 mg of control or experimental siRNA . Cells were exposed to transfection reagent for 16 h and then washed and cultured in 0, 0.5, 1.0 and 2.0 mM cisplatin for 6 h and harvested 24 h later. Luciferase activity was normalized to Renilla activity as previously described . Data points represent the average of triplicate transfections with similar results obtained in three independent experiments.
Microarray
Total RNA was isolated using TriReagent, and subsequent cleanup with RNeasy columns (Qiagen) according to the manufacturer's directions. Hybridizations were performed according to Affymetrix guidelines using the Human HG-U133A chip containing 22 500 unique genetic elements. Double-stranded cDNA was synthesized using Superscript II RT (Invitrogen). In vitro transcription labeling was performed with biotin-labeled nucleotides using the Bioarray High Yield RNA Labeling Kit (ENZO). Labeled RNA (20 ml) per sample was added to the hybridization cocktail, with a total of 15 mg hybridized to the chip (16 h, 451C). Two independent treated hybridizations were preformed. RMA analysis was performed using Gene Traffic software (Iobion), where raw data for each hybridization were normalized, background corrected, and filtered for signal intensity of 50 or greater in at least one comparison. Genes were considered changed with cisplatin with a fold-change of 2.0 or greater in one hybridization and 1.5 or greater in the second hybridization.
siRNA NT2/D1-specific siRNA was performed as described previously . Two independent siRNAs were designed that target sequences AAGACUCCAGUGGUAA UCUAC and CGGCAUGAACCGGAGGCCCAU of human p53. The siRNA duplex control used was the Scramble II sequence (Dharmacon). A final concentration of 150 nM siRNA was transfected using OligofectAMINE reagent (Invitrogen), as described previously .
Northern, RT-PCR, and Western analysis
Total RNA was harvested using TriReagent (Invitrogen). Northern hybridizations were performed with 5 mg RNA as previously described (Freemantle et al., 2002) . Expression levels of cisplatin responsive genes were measured by semiquantative RT-PCR. The cDNA was synthesized using Superscript II RT from 5 mg total RNA. PCR analysis was performed with Taq polymerase (Invitrogen) to varying cycle numbers within the linear range as previously described (Freemantle et al., 2002) . The sequences of primers are available on request. For Western analysis, cells were lysed in RIPA buffer and protein concentrations determined by Bradford technique. Proteins were analysed by SDS-PAGE as previously described (Curtin et al., 2001) . The p53 antibody (DO-1) and the FAS antibody were from Santa Cruz. The FDXR antibody was from Lab Frontier (Seoul Korea) and the PARP antibody (c-2-10) was from Biomol International.
